InvestSMART

PainChek Ltd (ASX: PCK) - Announcements

Current share price for PCK : $0.105 0.005 (5%)+

ASX company news and announcements for PainChek Ltd (PCK) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PainChek Ltd (PCK) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PainChek Ltd (PCK), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PainChek Ltd (PCK)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$22 PainChek receives $1.123 million R&D tax incentive refund 22 Jul 2026 8:29AM $0.100 $0.105 risen by 5%
$22 US MedTech leader Karen Holzberger appointed CEO 20 Jul 2026 8:58AM $0.105 $0.105 fallen by 0%
$22 Final Director's Interest Notice 8 Jul 2026 1:44PM $0.115 $0.105 fallen by 8.70%
$22 CEO Transition 6 Jul 2026 4:33PM $0.100 $0.105 risen by 5%
$22 Notification of cessation of securities - PCK 3 Jul 2026 3:24PM $0.105 $0.105 fallen by 0%
$22 Change of Director's Interest Notice x5 26 Jun 2026 5:12PM $0.100 $0.105 risen by 5%
$22 Notification regarding unquoted securities - PCK 26 Jun 2026 4:19PM $0.100 $0.105 risen by 5%
$22 PainChek secures initial Sabra US care facilities 4 Jun 2026 8:27AM $0.140 $0.105 fallen by 25%
$22 Notification regarding unquoted securities - PCK 28 May 2026 5:31PM $0.145 $0.105 fallen by 27.59%
$22 Initial Director's Interest Notice 26 May 2026 10:17AM $0.150 $0.105 fallen by 30%
$22 Lil Bianchi appointed Non-Executive Chair of PainChek 25 May 2026 8:50AM $0.140 $0.105 fallen by 25%
$22 Proposed issue of securities - PCK 22 May 2026 1:53PM $0.145 $0.105 fallen by 27.59%
$22 PainChek secures A$5.5m note to fund US expansion 22 May 2026 9:05AM $0.130 $0.105 fallen by 19.23%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 11:18AM $0.150 $0.105 fallen by 30%
$22 Notification of cessation of securities - PCK 14 Apr 2026 3:18PM $0.195 $0.105 fallen by 46.15%
$22 Landmark Sabra North America deployment targeting 20k beds 14 Apr 2026 9:19AM $0.150 $0.105 fallen by 30%
$22 Notification of cessation of securities - PCK 27 Mar 2026 2:34PM $0.195 $0.105 fallen by 46.15%
$22 PainChek reports material sales momentum in UK 26 Mar 2026 8:54AM $0.140 $0.105 fallen by 25%
$22 PainChek to present at NWR Virtual Healthcare Conference 24 Mar 2026 9:13AM $0.140 $0.105 fallen by 25%
$22 Notification of cessation of securities - PCK 4 Mar 2026 9:50AM $0.170 $0.105 fallen by 38.24%
$22 Half Yearly Report and Accounts 27 Feb 2026 2:19PM $0.170 $0.105 fallen by 38.24%
$22 Update - Notification regarding unquoted securities - PCK 12 Feb 2026 8:48AM $0.240 $0.105 fallen by 56.25%
$22 Notification regarding unquoted securities - PCK 11 Feb 2026 3:13PM $0.235 $0.105 fallen by 55.32%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 9:07AM $0.270 $0.105 fallen by 61.11%
$22 PainChek Business Update 30 Jan 2026 9:07AM $0.270 $0.105 fallen by 61.11%

1 - 25 of 466 results

Page 1 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.